Standard BioTools Inc. Interest Expense Operating
Standard BioTools Inc. (LAB) reported Interest Expense Operating of $26.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement
us-gaap:InterestExpenseOperating · last filed 2026-03-16
- Standard BioTools Inc. interest expense operating for the quarter ending 2025-12-31 was $5.00K, a 99.13% decline year-over-year.
- Standard BioTools Inc. interest expense operating for the quarter ending 2025-09-30 was $10.00K, a 98.83% decline year-over-year.
- Standard BioTools Inc. interest expense operating for the quarter ending 2025-06-30 was $9.00K, a 98.95% decline year-over-year.
- Standard BioTools Inc. interest expense operating for the quarter ending 2025-03-31 was $2.00K, a 99.81% decline year-over-year.
- Standard BioTools Inc. interest expense operating for fiscal 2025 was $26.00K, a 99.22% decline from fiscal 2024.
- Standard BioTools Inc. interest expense operating for fiscal 2024 was $3.32M, a 27.39% decline from fiscal 2023.
- Standard BioTools Inc. interest expense operating for fiscal 2023 was $4.57M, a 5.45% increase from fiscal 2022.
- Standard BioTools Inc. interest expense operating for fiscal 2022 was $4.33M.
| Period end | Interest Expense Operating 3 month | Interest Expense Operating 6 month | Interest Expense Operating 9 month | Interest Expense Operating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $15.00K derived: sum of 2 quarters · filed 2026-03-16 | $24.00K derived: sum of 3 quarters · filed 2026-03-16 | $26.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $10.00K 10-Q · filed 2025-11-04 | $19.00K derived: sum of 2 quarters · filed 2025-11-04 | $21.00K 10-Q · filed 2025-11-04 | $593.00K derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | $9.00K 10-Q · filed 2025-08-15 | $11.00K 10-Q · filed 2025-08-15 | $583.00K derived: sum of 3 quarters · filed 2026-03-16 | $1.44M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | $2.00K 10-Q · filed 2025-05-06 | $574.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.43M derived: sum of 3 quarters · filed 2026-03-16 | $2.29M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | $572.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.43M derived: sum of 2 quarters · filed 2026-03-16 | $2.28M derived: sum of 3 quarters · filed 2026-03-16 | $3.32M 10-K · filed 2026-03-16 |
| 2024-09-30 | $853.00K 10-Q · filed 2025-11-04 | $1.71M derived: sum of 2 quarters · filed 2025-11-04 | $2.74M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $858.00K 10-Q · filed 2025-08-15 | $1.89M 10-Q · filed 2025-08-15 | ||
| 2024-03-31 | $1.03M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $4.57M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $4.33M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |